Pro Share Advisors LLC Verve Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

$42.9 Billion
Q1 2025

A detailed history of Pro Share Advisors LLC transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 19,384 shares of VERV stock, worth $215,743. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,384

Previous 24,016 19.29%

Holding current value

$215,743

Previous $135,000 34.81%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 08, 2025	SELL	$4.57 - $8.63 $21,168 - $39,974	-4,632 Reduced 19.29%	19,384 $88,000
Q4 2024 Feb 13, 2025	BUY	$4.5 - $7.19 $25,164 - $40,206	5,592 Added 30.35%	24,016 $135,000
Q3 2024 Nov 13, 2024	BUY	$4.4 - $7.86 $19,434 - $34,717	4,417 Added 31.53%	18,424 $89,000
Q2 2024 Aug 13, 2024	SELL	$4.76 - $12.79 $17,559 - $47,182	-3,689 Reduced 20.85%	14,007 $68,000
Q1 2024 May 08, 2024	BUY	$10.81 - $17.96 $45,229 - $75,144	4,184 Added 30.97%	17,696 $235,000
Q4 2023 Feb 14, 2024	BUY	$8.84 - $18.7 $24,354 - $51,518	2,755 Added 25.61%	13,512 $188,000
Q3 2023 Nov 13, 2023	BUY	$11.42 - $20.82 $1,735 - $3,164	152 Added 1.43%	10,757 $142,000
Q2 2023 Aug 10, 2023	BUY	$13.34 - $19.9 $141,470 - $211,039	10,605 New	10,605 $198,000
Q4 2022 Feb 02, 2023	BUY	$17.85 - $40.7 $18,796 - $42,857	1,053 Added 10.47%	11,112 $215,000
Q3 2022 Nov 04, 2022	BUY	$15.63 - $41.49 $157,222 - $417,347	10,059 New	10,059 $345,000
Q2 2022 Aug 01, 2022	SELL	$11.14 - $23.17 $131,641 - $273,799	-11,817 Closed	0 $0
Q1 2022 May 10, 2022	BUY	$20.92 - $39.36 $33,367 - $62,779	1,595 Added 15.6%	11,817 $270,000
Q4 2021 Feb 08, 2022	BUY	$31.94 - $54.82 $326,490 - $560,370	10,222 New	10,222 $377,000

Others Institutions Holding VERV

# of Institutions

198

Shares Held

79.9M

Call Options Held

204K

Put Options Held

101K

View Full List

About Verve Therapeutics, Inc.

Ticker VERV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,942,300
Market Cap $667M
Description
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...

More about VERV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Verve Therapeutics, Inc. Transaction History